Inventiva
Inventiva Logo
About Inventiva
Inventiva SACA is a clinical-stage biopharmaceutical company specializing in the development of novel oral small molecule therapies for diseases with significant unmet medical need, including non-alcoholic steatohepatitis (NASH), fibrosis, lysosomal storage disorders, and oncology. Its lead candidate, Lanifibranor, is in Phase III trials for NASH, while Odiparcil is being developed for mucopolysaccharidoses type VI. Inventiva leverages a proprietary discovery engine and a robust pipeline of earlier-stage programs to advance innovative treatments.
Address
50 rue de Dijon,
Daix, 21121
France
Year founded
2012
Number of employees
100-200
Sector
Health Care
Industry Group
Pharmaceuticals, Biotechnology & Life Sciences
Industry
Biotechnology
Report inaccurate data
Request an update to help us keep the brand up-to-date.
